Anticoagulation in Patients With Venous Thromboembolism and Cancer (VICTORIE)

Pfizer

Status

Active, not recruiting

Conditions

Embolism

Neoplasms

Treatments

Drug: Dabigatran

Drug: Apixaban

Drug: LMWH

Drug: VKA

Drug: Edoxaban

Drug: Rivaroxaban

Study type

Observational

Funder types

Industry

Identifiers

NCT04618913

B0661150

VICTORIE (Other Identifier)

Details and patient eligibility

About

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

A VTE diagnosis
Active cancer or history of cancer
Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH
Age ≥ 18 years at the date of index VTE (Venous thromboembolic)

Exclusion criteria

Prior VTE diagnosis
Diagnosis of prior atrial fibrillation
Inferior Vena Cava (IVC) filter
Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed.
Pregnancy
More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date.
Patients with less than one day of follow up